1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Synercid IV Injection

Trade Name: SYNERCID

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antibiotic agent

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

EU Classification:

EU Indication of danger: Not classified

Label Elements

Hazard Statements: May form combustible dust concentrations in air

Other Hazards

Australian Hazard Classification (NOHSC):

No data available

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>EU Classification</th>
<th>GHS Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinupristin</td>
<td>120138-50-3</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>30</td>
</tr>
<tr>
<td>Dallopistin</td>
<td>112362-50-2</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>Not Listed</td>
<td>70</td>
</tr>
</tbody>
</table>

Additional Information: Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute andDelayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire. May include oxides of carbon nitrogen sulfur

Fire / Explosion Hazards: Dust can form an explosive mixture in air. Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters
During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures
Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions
Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting:
Remove all sources of ignition. Contain the source of the spill if it is safe to do so. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills:
Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling
Minimize dust generation and accumulation. Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities
Storage Conditions: Store as directed by product packaging.
Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters
The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Quinupristin
Pfizer Occupational Exposure Band (OEB): OEB 3 (control exposure to the range of 10ug/m³ to < 100ug/m³)

Dalfopristin
Pfizer Occupational Exposure Band (OEB): OEB 2 (control exposure to the range of 100ug/m³ to < 1000ug/m³)

Exposure Controls
Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.
9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder  Color: White to slightly yellow
Odor: No data available.  Odor Threshold: No data available.
Molecular Formula: Mixture  Molecular Weight: Mixture

Solvent Solubility: No data available
Water Solubility: Soluble
pH: 4.3-5.0 (10% aqueous solution)
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
Dalfopristin  Predicted Log P -1.33
Quinupristin  Predicted Log P -1.33
Decomposition Temperature (°C): No data available.
Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammability:
Autoignition Temperature (Solid) (°C): No data available
Flammability (Solids): No data available
Flash Point (Liquid) (°C): No data available
Upper Explosive Limits (Liquid) (% by Vol.): No data available
Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
Oxidizing Properties: None
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects
Short Term: May cause eye irritation. May cause skin irritation. May produce allergic reactions after systemic administration.
Known Clinical Effects: May cause effects similar to those generally seen in clinical use of antibiotics including gastrointestinal irritation, vomiting, transient diarrhea, nausea, and abdominal pain.

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)
11. TOXICOLOGICAL INFORMATION

Dalfopristin
1 Month(s)  Rat  Intravenous 10 mg/kg/day  NOAEL  None identified
1 Month(s)  Monkey  No route specified 25 mg/kg/day  NOAEL  No effects at maximum dose

Quinupristin
1 Month(s)  Rat  No route specified 1 mg/kg/day  NOAEL  None identified
1 Month(s)  Monkey  No route specified 16 mg/kg/day  NOAEL  No effects at maximum dose

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Dalfopristin
Fertility and Embryonic Development  Rat  No route specified 120 mg/kg/day  NOAEL  No effects at maximum dose
Fertility and Embryonic Development  Mouse  No route specified 40 mg/kg/day  NOAEL  No effects at maximum dose
Fertility and Embryonic Development  Rabbit  No route specified 12 mg/kg/day  NOAEL  No effects at maximum dose

Quinupristin
Fertility and Embryonic Development  Rat  No route specified 120 mg/kg/day  NOAEL  No effects at maximum dose
Fertility and Embryonic Development  Mouse  No route specified 40 mg/kg/day  NOAEL  No effects at maximum dose
Fertility and Embryonic Development  Rabbit  No route specified 12 mg/kg/day  NOAEL  No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Dalfopristin
Bacterial Mutagenicity (Ames)  Bacteria  Negative
HGPRT Forward Gene Mutation Assay  Chinese Hamster Ovary (CHO) cells  Negative
Unscheduled DNA Synthesis  Rat Hepatocyte  Negative
Chromosome Aberration  Chinese Hamster Ovary (CHO) cells  Positive
Micronucleus  Mouse Bone Marrow  Negative

Quinupristin
Bacterial Mutagenicity (Ames)  Bacteria  Negative
HGPRT Forward Gene Mutation Assay  Chinese Hamster Ovary (CHO) cells  Negative
Unscheduled DNA Synthesis  Rat Hepatocyte  Negative
Chromosome Aberration  Chinese Hamster Ovary (CHO) cells  Negative
Micronucleus  Mouse Bone Marrow  Negative

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Partition Coefficient: (Method, pH, Endpoint, Value)
13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class: Non-controlled
This product has been classified in accordance with the hazard criteria of the CPR and the SDS contains all of the information required by the CPR.

Quinupristin
- CERCLA/SARA 313 Emission reporting: Not Listed
- California Proposition 65: Not Listed
- Standard for the Uniform Scheduling for Drugs and Poisons: Schedule 4
- EU EINECS/ELINCS List: Not Listed

Dalfopristin
- CERCLA/SARA 313 Emission reporting: Not Listed
15. REGULATORY INFORMATION

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>California</td>
<td>Not Listed</td>
</tr>
<tr>
<td>Proposition 65</td>
<td></td>
</tr>
<tr>
<td>Standard for</td>
<td>Schedule 4</td>
</tr>
<tr>
<td>the Uniform</td>
<td></td>
</tr>
<tr>
<td>Scheduling</td>
<td></td>
</tr>
<tr>
<td>for Drugs and</td>
<td></td>
</tr>
<tr>
<td>Poisons:</td>
<td></td>
</tr>
<tr>
<td>EU EINECS/ELINCS</td>
<td>Not Listed</td>
</tr>
<tr>
<td>List</td>
<td></td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.

Revision date: 27-May-2015


Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet